Track the Neumora Therapeutics, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €284.7m. The latest transaction was disclosed on 21 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Aurora Daljit Singh. Every trade is openly available.
94
Insider Decl.
n/a
Thresholds
€47m
19 ops.
Buy Volume
€2m
26 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Neumora Therapeutics, Inc. Buy (bullish), based on 7 analysts. Average price target: US$6.14.
23Σ signal
Buys €47m€2m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
34,987 shares@ US$1.58590.020% mcap4.3% of flowCommon StockSEC:0001610717-26-000362:12
25 of 94 declarations
Acerca de Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para trastornos neurológicos. Utiliza enfoques basados en la ciencia de datos para identificar nuevas terapias.